AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9314089 — intervention group
Group type: COMPARATOR
Intervention: Cardizem CD (extended-release diltiazem)
Number of subjects: 14
Study 9314089 — intervention group
Group type: COMPARATOR
Intervention: Dilacor XR (extended-release diltiazem)
Number of subjects: 14
Study 8353660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg daily (5 mg morning and evening for 2 weeks)
Number of subjects: 124
Study 8353660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 8353660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 124
Study 3319859 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 14
Study 3319859 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CI)
Number of subjects: 14
Study 3319859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CSII and CI)
Number of subjects: 14
Study 2195863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 150 mg/day
Number of subjects: 18
Study 2195863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2195863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 18
Study 1149482 — intervention group
Group type: EXPERIMENTAL
Intervention: Eryfer (fast-release iron capsule) - 2 capsules (100 mg. elemental iron) daily for 30 days
Number of subjects: 60
Study 1149482 — intervention group
Group type: COMPARATOR
Intervention: Ferro-Gradumet (slow-release iron tablet) - 1 tablet (105 mg. elemental iron) daily for 30 days
Number of subjects: 60
Study 31874180 — intervention group
Group type: EXPERIMENTAL
Intervention: Late night sleep loss (four-hour sleep during the first night-half)
Number of subjects: 11
Study 31874180 — intervention group
Group type: EXPERIMENTAL
Intervention: Early night sleep loss (four-hour sleep during the second night-half)
Number of subjects: 11
Study 31874180 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sleep (eight-hour sleep)
Number of subjects: 11
Study 31350934 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB intervention (behavioral ED risk factor reduction program)
Number of subjects: 481
Study 31350934 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 481
Study 28653586 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal replacement (HPMR)
Number of subjects: 122
Study 26009990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free phone conversation
Number of subjects: 100
Study 26009990 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld phone conversation
Number of subjects: 100
Study 26009990 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no phone conversation)
Number of subjects: 100
Study 24224449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (vitamin C) supplementation at a dose of 600 mg per 24 hours during chemotherapy
Number of subjects: 25
Study 24224449 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 healthy individuals)
Number of subjects: 25
Study 21633770 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-added parenteral nutrition (PN)
Number of subjects: 270
Study 21633770 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (PN)
Number of subjects: 270
Study 21633770 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-added PN
Number of subjects: 270
Study 21633770 — intervention group
Group type: COMPARATOR
Intervention: Standard PN
Number of subjects: 270
Study 19541586 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 60
Study 19541586 — intervention group
Group type: COMPARATOR
Intervention: Direct lateral approach
Number of subjects: 60
Study 16979993 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (MPS) [1.08-1.44 g/d]
Number of subjects: 112
Study 16979993 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) [1.5-2.0 g/d]
Number of subjects: 112
Study 15520535 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated monitoring system for chronic kidney-insufficient patients
Number of subjects: 0
Study 10938494 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate CR/XL added to standard therapy
Number of subjects: 3991
Study 10938494 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 3991
Study 9052464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical pentosanpolysulphate (PPS) 300 mg in 50 mL of 0.9% sodium chloride, applied twice a week for 3 months
Number of subjects: 20
Study 9052464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9052464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical pentosanpolysulphate (PPS)
Number of subjects: 20
Study 9052464 — intervention group
Group type: COMPARATOR
Intervention: No treatment (after stopping PPS)
Number of subjects: 20
Study 8398961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (5 mg in 25 ml dilution)
Number of subjects: 20
Study 8398961 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 ml saline)
Number of subjects: 20
Study 3742049 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/d for 8 weeks)
Number of subjects: 16
Study 3742049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 weeks)
Number of subjects: 16
Study 30003481 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 196
Study 30003481 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification arm
Number of subjects: 196
Study 30003481 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification arm with PCP data sharing
Number of subjects: 196
Study 28480658 — intervention group
Group type: COMPARATOR
Intervention: Hormonal Therapy (HT) alone (0.625 mg/day of conjugated equine estrogen and 2.5 mg/day of medroxyprogesterone acetate)
Number of subjects: 344
Study 28480658 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with Alendronate (ALEN) and Hormonal Therapy (HT) (10 mg/day of ALEN)
Number of subjects: 344
Study 28480658 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with Alendronate (ALEN) and Hormonal Therapy (HT)
Number of subjects: 344
Study 25715019 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (PoCUS)
Number of subjects: 0
Study 25715019 — intervention group
Group type: COMPARATOR
Intervention: Stethoscope
Number of subjects: 0
Study 23991661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (initial doses of 150, 220, or 300 mg twice daily, adjusted based on kidney function)
Number of subjects: 252
Study 23991661 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (doses adjusted to obtain an INR of 2 to 3 or 2.5 to 3.5)
Number of subjects: 252
Study 20420722 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 53
Study 20420722 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 53
Study 19383314 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor inhibitors
Number of subjects: 0
Study 19383314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical characteristics
Number of subjects: 0
Study 16621768 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation (4 g/m2/day) during chemotherapy
Number of subjects: 21
Study 16621768 — intervention group
Group type: COMPARATOR
Intervention: No glutamine supplementation (control)
Number of subjects: 21
Study 16621768 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation
Number of subjects: 21
Study 11957440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (I group)
Number of subjects: 85
Study 11957440 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 9795483 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 31
Study 9795483 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard
Number of subjects: 31
Study 7861879 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine feedback on test-group A (electrocardiography, endoscopy, cervical smears, and allergy tests)
Number of subjects: 79
Study 7861879 — intervention group
Group type: COMPARATOR
Intervention: Routine feedback on test-group B (radiographic and ultrasonographic tests)
Number of subjects: 79
Study 2227076 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ursodeoxycholic acid (UDCA) twice daily for 14 days
Number of subjects: 10
Study 2227076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 365214 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 15
Study 365214 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 15
Study 30190512 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (ADV-TK, 5 × 10^12/ml) administered one or two times before operation
Number of subjects: 77
Study 30190512 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control group)
Number of subjects: 77
Study 29161072 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART intervention
Number of subjects: 222
Study 29161072 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control
Number of subjects: 222
Study 26620101 — intervention group
Group type: EXPERIMENTAL
Intervention: BIT225 (400 mg twice daily)
Number of subjects: 21
Study 26620101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 25277025 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-order control
Number of subjects: 36
Study 25277025 — intervention group
Group type: COMPARATOR
Intervention: First-order control
Number of subjects: 36
Study 22212862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation of Phlebodium decumanum during high-intensity exercise
Number of subjects: 0
Study 19895618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 21
Study 19895618 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2%
Number of subjects: 21
Study 19895618 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 21
Study 18172370 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic pulsating light
Number of subjects: 163
Study 18172370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 15221206 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise regimen (supervised, progressive exercises three times per week plus home program for 12 months)
Number of subjects: 120
Study 15221206 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise regimen
Number of subjects: 120
Study 15221206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 120
Study 12065345 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP, 200 to 800 microg/d (n = 354)
Number of subjects: 473
Study 12065345 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP, 400 to 1,600 microg/d (n = 119)
Number of subjects: 473
Study 9468743 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent reinforcement for cocaine abstinence and attendance at prenatal visits
Number of subjects: 12
Study 9468743 — intervention group
Group type: COMPARATOR
Intervention: Standard multifaceted treatment including behaviorally based drug counseling and weekly prenatal visits
Number of subjects: 12
Study 10172545 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug supply and cost sharing system
Number of subjects: 11772
Study 10172545 — intervention group
Group type: COMPARATOR
Intervention: Control district with only government drug supply
Number of subjects: 11772
Study 2240642 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (75 micrograms)
Number of subjects: 39
Study 2240642 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (5 mL)
Number of subjects: 39
Study 365855 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Number of subjects: 30
Study 365855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31994989 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline-malate (CM) supplementation (12g dextrose + 8g CM)
Number of subjects: 28
Study 31994989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) (12g dextrose)
Number of subjects: 28
Study 31109368 — intervention group
Group type: EXPERIMENTAL
Intervention: TMQLB group 1 (0.4 ml/kg body weight 0.5% ropivacaine)
Number of subjects: 120
Study 31109368 — intervention group
Group type: EXPERIMENTAL
Intervention: TMQLB group 2 (0.6 ml/kg body weight 0.5% ropivacaine)
Number of subjects: 120
Study 31109368 — intervention group
Group type: COMPARATOR
Intervention: TPVB control group (0.4 ml/kg body weight 0.5% ropivacaine at vertebra T10)
Number of subjects: 120
Study 28779944 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga and working memory training
Number of subjects: 45
Study 28779944 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 45
Study 28779944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 26501785 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected vaginal/anal sex at last sexual occasion (LSO)
Number of subjects: 480
Study 26501785 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use at last sexual occasion (LSO)
Number of subjects: 480
Study 23954912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral α‐methyl‐para‐tyrosine (catecholamine depletion)
Number of subjects: 28
Study 21471564 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vinorelbine-cisplatin)
Number of subjects: 1149
Study 19379517 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychology (in-home videoconferencing technology)
Number of subjects: 224
Study 19379517 — intervention group
Group type: COMPARATOR
Intervention: Same-Room (traditional face-to-face services)
Number of subjects: 224
Study 17692155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg, two tablets daily for 8 weeks, then one tablet daily for 4 weeks)
Number of subjects: 122
Study 17692155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets daily for 8 weeks)
Number of subjects: 122
Study 15220243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 48
Study 15220243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11204585 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (ambulating for > or = 4 hours per day)
Number of subjects: 129
Study 11204585 — intervention group
Group type: COMPARATOR
Intervention: Strict immobilization for 4 days
Number of subjects: 129
Study 11204585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (immobilized and ambulating)
Number of subjects: 129
Study 9708399 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV-SGC 1200 mg three times a day for 16 weeks
Number of subjects: 171
Study 9708399 — intervention group
Group type: COMPARATOR
Intervention: SQV-HGC 600 mg three times a day for 16 weeks
Number of subjects: 171
Study 9708399 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV-SGC
Number of subjects: 171
Study 9708399 — intervention group
Group type: COMPARATOR
Intervention: SQV-HGC
Number of subjects: 171
Study 9708399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 171
Study 1890497 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 18
Study 1890497 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 18
Study 1890497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6138916 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibenzyline 10 micrograms orally 6-8 hours after operation and again the next day about 18 hours later (total abdominal hysterectomy)
Number of subjects: 81
Study 6138916 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibenzyline 10 micrograms orally 6-8 hours after operation and again the next day about 18 hours later (vaginal hysterectomy)
Number of subjects: 81
Study 31287580 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily full-body application of an emollient with ceramide and amino acids
Number of subjects: 100
Study 31287580 — intervention group
Group type: COMPARATOR
Intervention: Standard skin care (control group)
Number of subjects: 100
Study 27568322 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with cisplatin and fluoropyrimidines
Number of subjects: 0
Study 27568322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0
Study 27568322 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 0
Study 27568322 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Number of subjects: 0
Study 27568322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 27568322 — intervention group
Group type: EXPERIMENTAL
Intervention: TKIs (sunitinib, sorafenib, regorafenib, apatinib)
Number of subjects: 0
Study 26677724 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy (SE) based intervention
Number of subjects: 52
Study 25048952 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag (100mg loading dose followed by 20, 40, or 80 mg/day on days 2‐7)
Number of subjects: 130
Study 25048952 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag (80 mg loading dose followed by 10 mg/day for days 2‐7, or 20mg/day for days 2‐4)
Number of subjects: 130
Study 25048952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Cohort A)
Number of subjects: 130
Study 25048952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Cohort B)
Number of subjects: 130
Study 22751878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pressure (ICP) monitoring
Number of subjects: 4667
Study 22751878 — intervention group
Group type: COMPARATOR
Intervention: Expected hospital ICP monitoring rates
Number of subjects: 4667
Study 22751878 — intervention group
Group type: COMPARATOR
Intervention: Observed hospital ICP monitoring rates
Number of subjects: 4667
Study 22751878 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 1 year and older
Number of subjects: 4667
Study 20018286 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg/daily
Number of subjects: 29
Study 20018286 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20mg/daily
Number of subjects: 29
Study 18600215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/day) at bedtime
Number of subjects: 180
Study 16123546 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Rehabilitation Unit (SRU)
Number of subjects: 178
Study 16123546 — intervention group
Group type: COMPARATOR
Intervention: General Rehabilitation Ward (GRW)
Number of subjects: 178
Study 16123546 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Independence Measure
Number of subjects: 178
Study 16123546 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Impairment Assessment Set
Number of subjects: 178
Study 16123546 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 178
Study 16123546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of hospitalization
Number of subjects: 178
Study 12714817 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU (60 mg/kg body weight) for 48 hours
Number of subjects: 55
Study 12714817 — intervention group
Group type: COMPARATOR
Intervention: Folinic acid (FA) (500 mg/m2) for 2 hours and 5-FU (2600 mg/m2) for 24 hours
Number of subjects: 55
Study 10385499 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 134
Study 10385499 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 134
Study 9106574 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV+CPAP
Number of subjects: 10
Study 9106574 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV
Number of subjects: 10
Study 9106574 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 10
Study 8239308 — intervention group
Group type: EXPERIMENTAL
Intervention: BMY 21,502 (300 mg tid)
Number of subjects: 69
Study 8239308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 8239308 — intervention group
Group type: EXPERIMENTAL
Intervention: BMY 21,502
Number of subjects: 69
Study 2870352 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg (doubled if not effective after 4 weeks)
Number of subjects: 436
Study 2870352 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (doubled if not effective after 4 weeks)
Number of subjects: 436
Study 2870352 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg (doubled if not effective after 4 weeks)
Number of subjects: 436
Study 29534310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 16 weeks
Number of subjects: 0
Study 29534310 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon lambda 4 (IFNL4) CC genotype
Number of subjects: 0
Study 29534310 — intervention group
Group type: EXPERIMENTAL
Intervention: CC genotype patients
Number of subjects: 0
Study 29534310 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-CC genotype patients
Number of subjects: 0
Study 26564169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSA patients
Number of subjects: 39
Study 26564169 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 24827746 — intervention group
Group type: EXPERIMENTAL
Intervention: Bofutsushosan
Number of subjects: 111
Study 24827746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 22652101 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver clear nylon dressing (SCND) applied from Day 1 of radiation therapy until 2 weeks after treatment completion
Number of subjects: 42
Study 22652101 — intervention group
Group type: COMPARATOR
Intervention: Standard skin care (sulfadiazine cream applied at the time of skin dermatitis)
Number of subjects: 42
Study 22652101 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver clear nylon dressing (SCND)
Number of subjects: 42
Study 20590587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg x kg(‐1) + Quinidine (CYP2D6 inhibitor)
Number of subjects: 10